Neurology Prior Auth: Imaging and Biologics

The Neurology Prior Auth Burden: Scope and Scale

Neurology prior authorization encompasses a uniquely broad range of services — from imaging (brain and spine MRI) to electrodiagnostic testing (EMG/NCS) to high-cost biologic therapies that can exceed $60,000-$120,000 per patient per year. The volume is substantial: a neurologist managing a mixed panel of MS, migraine, epilepsy, and neuropathy patients may submit 25-35 prior authorization requests per week.

The financial stakes of denied or delayed authorizations in neurology are higher than most specialties because the therapies involved are often time-sensitive in ways that imaging approvals in other specialties are not. An MS patient whose natalizumab infusion is delayed by 2 weeks while an authorization dispute is resolved may experience breakthrough disease activity during that gap. A migraine patient denied a CGRP monoclonal antibody and forced to retry a preventive medication they have already failed may suffer months of unnecessary headache burden before the payer's step therapy requirements are re-satisfied.

The prior authorization landscape in neurology is organized around four major categories: 1. Advanced neuroimaging: brain MRI, spine MRI, functional MRI, PET brain 2. Electrodiagnostic testing: EMG/NCS, SSEP, VEP 3. MS disease-modifying therapies (DMTs): high-efficacy and standard-efficacy agents 4. Migraine biologics and procedures: CGRP monoclonal antibodies, onabotulinumtoxinA (Botox) for chronic migraine

Each category has its own documentation requirements, step therapy protocols, and peer-to-peer review dynamics. Practices that build category-specific submission packages and track denial rates by category and payer achieve meaningfully better outcomes than practices using generic authorization processes.

Brain and Spine MRI Prior Authorization

Brain and spine MRI are the highest-volume imaging prior authorization request in neurology and among the most commonly denied by commercial payers. The denial mechanism is almost always the same: the payer's clinical criteria require more specific clinical indication documentation than the ordering neurologist has provided in the authorization request.

Brain MRI (CPT 70553 with and without contrast) — required documentation by indication:

New headache evaluation: documentation must specify that the headache is new, has changed in character, meets red flag criteria (thunderclap onset, associated fever/neck stiffness, progressive worsening over days, headache in patient over 50 without prior history, associated neurological deficits, onset with exertion). A standard "migraine headache" indication without red flag documentation is frequently denied as not meeting imaging criteria.

MS monitoring: documentation must reference the patient's confirmed MS diagnosis (CDMS criteria met), current DMT, last MRI date and findings, and clinical rationale for the new study (e.g., new symptoms suggesting relapse, surveillance per MS monitoring protocol, treatment initiation or switch evaluation). Payers approve MS surveillance MRIs at specific intervals (typically every 12-24 months for stable RRMS, more frequently for active disease).

Cognitive evaluation / dementia workup: documentation of cognitive symptoms, MMSE or MoCA score, exclusion of metabolic causes (B12, TSH, metabolic panel), and age/risk factors for dementia. Payers require evidence that a clinical evaluation has been performed before approving imaging.

Medicare AUC compliance: brain and spine MRI ordered for non-emergent indications in Medicare FFS patients require documentation of Appropriate Use Criteria consultation using a CMS-approved CDSM. The AUC rating and CDSM identifier must be reported on the claim. See prior discussion of AUC requirements under cardiology.

EMG and Nerve Conduction Studies Prior Authorization

Electromyography (EMG, CPT 95860-95864) and nerve conduction studies (NCS, CPT 95907-95913) are the primary diagnostic tools for evaluating peripheral neuropathy, radiculopathy, plexopathy, neuromuscular junction disorders, and myopathy. Despite being lower cost than MRI, commercial payers increasingly require prior authorization for these studies.

EMG/NCS authorization — required clinical documentation:

Peripheral neuropathy evaluation: specify symptom type (symmetric vs. asymmetric, length-dependent vs. non-length-dependent), symptom duration, prior workup (metabolic panel, B12, HbA1c, TSH, protein electrophoresis), and whether the study will change management. Payers frequently deny EMG/NCS for neuropathy when the clinical note does not explicitly state how the results will affect treatment decisions.

Radiculopathy evaluation: documentation of radicular symptoms (dermatomal distribution, neurological deficits), failure of conservative management, MRI findings if available (or rationale for EMG when MRI is inconclusive or shows multilevel disease), and the specific clinical question (confirm radiculopathy level, rule out superimposed neuropathy, assess severity for surgical planning).

Carpal tunnel syndrome confirmation: most payers require prior clinical diagnosis attempt (physical exam findings: Tinel's, Phalen's, thenar atrophy, sensory loss) and consideration of clinical diagnosis alone before requiring electrodiagnostic confirmation. For surgical candidacy evaluation, EMG/NCS is widely covered.

Myopathy and neuromuscular junction evaluation: CK elevation, proximal weakness pattern, myopathic features on exam — documentation of these clinical findings supports EMG/NCS authorization for myopathy evaluation. For MG/Lambert-Eaton evaluation, serologic testing (AChR antibodies, VGCC antibodies) should be ordered concurrently and the authorization request should note the clinical syndrome.

Authorization turnaround for EMG/NCS: 3-5 business days standard, 24-48 hours urgent. For patients with rapidly progressive weakness (possible GBS, AIDP), escalate to urgent clinical review with documented neurological emergency language.

MS Disease-Modifying Therapy Prior Authorization

MS disease-modifying therapy (DMT) prior authorization is the most administratively intensive aspect of MS care. High-efficacy agents — natalizumab (Tysabri), ocrelizumab (Ocrevus), ofatumumab (Kesimpta), siponimod (Mayzent), cladribine (Mavenclad), and alemtuzumab (Lemtrada) — typically cost $70,000-$120,000 per patient per year and require detailed clinical justification for approval.

Standard documentation requirements for MS DMT authorization:

1. Confirmed MS diagnosis: CDMS criteria (McDonald 2017 criteria preferred) — must specify MS type (RRMS, SPMS, PPMS) and relevant clinical/MRI features 2. Disease activity evidence (for high-efficacy agents): relapse history in prior 12-24 months, MRI evidence of active disease (Gd-enhancing lesions, new T2 lesions compared to prior MRI), or functional progression 3. Prior therapy trial (for high-efficacy agents requiring step therapy): many payers require documented trial of at least one standard-efficacy agent (interferon beta, glatiramer acetate, teriflunomide, dimethyl fumarate) before approving high-efficacy therapy. Document: agent tried, dose, duration, reason for discontinuation (breakthrough disease, intolerance, or side effects) 4. JC virus antibody status (specifically for natalizumab): Anti-JCV antibody index must be documented, as PML risk stratification is a medical necessity consideration. High JCV index (>0.9) may affect payer approval criteria for natalizumab. 5. EDSS score: Expanded Disability Status Scale — document current functional status. Some payers set maximum EDSS thresholds for specific agents.

Re-authorization requirements: MS DMTs require re-authorization every 6-12 months depending on payer. Prepare re-authorization documentation proactively: updated relapse history, most recent MRI comparison, current EDSS, side effect/tolerability assessment, and clinical rationale for continuing the current agent.

Step therapy challenge for high-efficacy agents: when the neurologist believes a patient should start on a high-efficacy agent (e.g., highly active RRMS with severe relapses or aggressive MRI activity), the step therapy requirement creates a clinical dilemma. File a step therapy exception request with documentation of: the clinical urgency (highly active disease that warrants immediate high-efficacy therapy), the risks of delay (relapse during standard agent trial), and clinical guidelines supporting early high-efficacy treatment (ECTRIMS/EAN 2023 guidelines support early high-efficacy therapy for high-activity RRMS).

Migraine Biologic Prior Authorization: CGRP Monoclonal Antibodies

CGRP monoclonal antibodies — erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti) — represent a major advance in migraine prevention and are now first-line recommendations per AHS guidelines for patients with frequent episodic and chronic migraine. However, prior authorization requirements for these agents remain among the most burdensome in neurology, with commercial payer approval rates ranging from 55-80% on first submission depending on documentation quality.

Standard CGRP biologic authorization documentation:

1. Migraine diagnosis confirmation: ICD-10 G43.x with ICHD-3 criteria met — document headache frequency (days per month), duration, severity, associated features (nausea, photophobia, phonophobia, aura). Specify episodic vs. chronic (15+ headache days/month per ICHD-3).

2. Headache calendar data: prior 3 months of headache diary or clinically documented headache frequency. Most payers require documented headache frequency before approving preventive therapy. If the patient has been on a paper diary, convert to documented monthly headache day counts in the chart.

3. Prior preventive therapy failures: the most critical documentation element. Most commercial payers require 2-3 failed oral preventive therapy trials before approving CGRP biologics. Required documentation for each failed agent: agent name and dose, treatment duration (must be adequate: typically 6-8 weeks at therapeutic dose minimum), reason for failure (inadequate efficacy or intolerable side effects). Common required agents: amitriptyline, topiramate, propranolol, metoprolol, valproate, nortriptyline, venlafaxine. Practices must document these trials in the clinical note — authorization reviewers cannot access the patient's prior medical records.

4. Acute medication use and MOH assessment: document current acute medication (triptan type, frequency, total monthly use). Excessive acute medication use (>10 days/month) may be flagged by payers as a MOH contributor; document that MOH has been addressed or that the agent is being used within guidelines.

Re-authorization and treatment response documentation: at 3 months, payers require documented treatment response for continuation authorization. The standard threshold: ≥50% reduction in monthly migraine days. Use RTM migraine diary data as objective documentation of response — a patient's 90-day RTM migraine frequency chart is stronger evidence than a clinician's retrospective summary.

OnabotulinumtoxinA (Botox) for Chronic Migraine: Medicare and Commercial Criteria

OnabotulinumtoxinA (Botox, CPT 64615 + J0585) for chronic migraine prevention was FDA-approved in 2010 (PREEMPT protocol, 155-195 units every 12 weeks) and is covered by Medicare and most commercial payers — with specific prior authorization requirements that vary significantly by payer.

Medicare does not require step therapy to CGRP biologics before Botox — a patient can receive Botox as first biologic therapy if they have failed two oral preventives. This differs from some commercial payers that require CGRP biologic trial before Botox for patients who qualify for both.

Commercial payer Botox criteria generally mirror Medicare but add: - Prior failure of specific named oral preventives (typically topiramate + one additional agent) - Some payers require prior trial of at least one CGRP monoclonal antibody before Botox (the reverse of Medicare) - Documentation of functional impairment from chronic migraine (MIDAS score ≥11 or equivalent)

Re-authorization every 12 weeks: prepare documentation proactively before each Botox session. The re-auth must include: headache frequency comparison since last injection (from diary or clinical documentation), side effects or tolerability, and neurologist attestation that treatment is providing clinical benefit. A patient showing <30% reduction in headache days on Botox should have treatment response discussed with the patient before the next authorization cycle, as some payers will deny re-authorization for insufficient response.

Billing the Botox injection: bill 64615 (chemodenervation of muscle, migraine) for the injection service. Bill J0585 for the onabotulinumtoxinA drug units administered (per unit). Document the number of units injected at each anatomical location per the PREEMPT protocol — this documentation is audited by payers and Medicare.

Step Therapy Exceptions and Prior Auth Appeals in Neurology

Step therapy — the payer requirement that less expensive therapies be tried before more expensive therapies are approved — creates particular clinical tension in neurology because the therapies that step therapy delays are often time-sensitive, and the consequences of delay can include irreversible neurological damage (MS relapse with incomplete recovery, cluster headache attacks that resist later treatment).

All 50 states have enacted step therapy exception laws that require commercial payers to grant a step therapy exception when specific clinical criteria are met. The typical standard for exception approval is: - The required step therapy agent is contraindicated or likely to be contraindicated based on the patient's medical history - The patient previously tried and failed the required agent (prior therapy failure exception) - The required step therapy is expected to cause an adverse reaction or harm - The patient is stable on an ongoing therapy — switching would cause clinical instability - The required step therapy is otherwise not clinically appropriate

Neurology-specific step therapy exception arguments:

For MS high-efficacy DMT: "Patient presents with highly active RRMS (3 relapses in 12 months, Gd-enhancing lesions on current MRI). ECTRIMS/EAN 2023 guidelines recommend early high-efficacy therapy for this clinical profile. Step therapy to standard-efficacy agents poses unacceptable risk of accumulating irreversible disability during the trial period. Requesting exception for direct approval of [natalizumab/ocrelizumab]."

For CGRP biologic after 2 (not 3) oral preventive failures: "Patient has failed topiramate (side effects: cognitive impairment preventing work) and propranolol (side effects: exacerbation of asthma). A third oral preventive trial would expose the patient to additional months of disability and risk of medication overuse headache. AHS guidelines support CGRP biologic initiation after failure of two oral preventives."

Peer-to-peer review for neurology denials: request peer-to-peer review within 48-72 hours of denial. Neurology peer-to-peer reviews are more effective with subspecialty-trained reviewers — request that the payer assign a neurologist reviewer (not a general internist) for MS DMT or complex migraine biologic appeals. Document the request in writing.

Building a Neurology Prior Auth Infrastructure

Systematic prior authorization management in neurology requires dedicated processes and trained staff — not reactive, case-by-case administrative work. Practices with a structured prior auth function achieve 15-25% higher first-pass approval rates and 40-60% lower administrative time per authorization than practices managing auth reactively.

Core infrastructure components:

Neurology-trained authorization coordinator: a staff member with specific knowledge of MS DMT requirements, CGRP biologic step therapy standards, and brain/spine MRI documentation requirements. General authorization coordinators without neurology training make documentation errors in submission packages that produce preventable denials. Investment in neurology-specific training (AAPC prior authorization certificate programs, payer-specific webinars) pays back in first-pass approval rate improvements.

Payer-specific authorization matrix: a reference document (updated quarterly) showing each major payer's prior auth requirements for each major neurology service category. MS DMT requirements for Aetna differ from BCBS differ from UHC — the matrix prevents the wrong documentation package being submitted to the wrong payer.

Clinical documentation templates: neurology-specific templates for each major authorization request type. A neurologist who fills in a structured template for a natalizumab authorization — answering: MS type, diagnosis date, relapse history (past 12 months), MRI activity (past 12 months), prior DMT trials (agent, dose, duration, discontinuation reason), JCV antibody index, current EDSS — will generate complete authorization packages consistently. Free-text authorization requests from neurologists who are not trained in documentation specifics produce the highest denial rates.

Authorization status tracker: a weekly review meeting (15-20 minutes) between the authorization coordinator and practice manager reviewing: authorizations submitted this week (count, by service category), authorizations approved (count, days to approval, by payer), authorizations denied (count, denial reason, status of appeal), and procedures approaching within 5 days without authorization confirmation (urgent action items).

Target metrics: first-pass approval rate ≥82% overall, ≥90% for brain/spine MRI; peer-to-peer reversal rate ≥55% for denied MS DMT requests; no procedures performed without authorization (exception: emergency/urgent clinical situations documented in chart).